substance abuse

First Opinion By Ian Tong

In defense of not treating everyone the same

First Opinion By Kushal Kadakia and Harlan M. Krumholz

Reforms needed for FDA’s regulation of medical devices

In the Lab By Andrew Joseph

We’ll know more soon about Omicron. Here’s how to interpret the coming flood of data

Health By Megan Molteni

‘Just stupid stuff’: Logistics and lack of testing stymied finding the Omicron variant in the U.S.

Pharmalot By Ed Silverman

Former Immunomedics executives are charged with insider trading

Politics By Nicholas Florko

Califf, nominee to lead FDA, asks Woodcock to stay in leadership role if he’s confirmed

Health Tech By Katie Palmer

Virtual care companies rush to ease access to Covid-19 antivirals

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron